
Michelson Diagnostics Showcases VivoSight OCT Imaging Technology at the 24th European Academy of Dermatology and Venereology (EADV) Congress

Data from New Dynamic OCT Study Reveals Changes in Skin Blood Vessels in Real Time

Maidstone, UK, 8th October 2015 – Michelson Diagnostics, a medical device company focused on applications of multi-beam Optical Coherence Tomography ('OCT') technology, today announces that multiple abstracts involving its VivoSight scanner will be presented at the 24th European Academy of Dermatology and Venereology Congress in Copenhagen, Denmark (7-11 October, 2015).

For the first time, Michelson Diagnostics and its collaborators will reveal data showing that its Dynamic OCT imaging technology is able to visualise in real-time the structure of blood vessels beneath the surface of the skin, as well as the real-time effects of a therapeutic agent on this vasculature. This breakthrough imaging development has the potential to assist dermatologists in the detection and prognosis of melanoma as well as monitoring the effectiveness of treatments for multiple skin conditions, including eczema, rosacea, psoriasis and wounds.

"The data being presented at EADV demonstrates the broad applicability of the VivoSight OCT technology and the ability to produce images of the skin previously unavailable using existing scanning techniques. By integrating our Dynamic OCT technology with the VivoSight point-of-care scanner, we have significantly expanded our potential market segments," noted Andy Hill, CEO of Michelson Diagnostics. "In particular, our Dynamic OCT technology provides dermatologists with the capability to visualise blood vessel structures and changes to their appearance following a treatment in real time. We have already seen collaborators use this tool to help confirm the presence and stage of melanoma."

Michelson Diagnostics will be demonstrating the VivoSight OCT scanner with probe equipped with new micro-camera on booth number 153 in the EADV exhibition hall.

For further information

Michelson Diagnostics

Andy Hill, Chief Executive Officer

Tel: +44 (0)20 8308 1695

Halsin Partners

Mike Sinclair

Tel: +44 (0)20 318 2955

Notes to editors

Posters presented at EADV

- P0909 Diagnostic accuracy of optical coherence tomography in differentiating normal skin from non melanoma skin cancer
 - Olsen, J (Roskilde, Denmark)
- P0921 Induced morphologic changes in skin vasculature imaged by speckle variance optical coherence tomography
 - Themstrup L (Roskilde, Denmark)

- P1924 Speckle variance optical coherence tomography imaging of normal facial skin treated with Brimonidine Tartrate 0.33% gel visualises morphologic changes in skin vasculature
 - Themstrup, L (Roskilde, Denmark)

Presentations at EADV

Saturday 10 October, 10:30 am FC06

- Microvascular remodelling related with tumour thickness and pattern of growth in melanoma and basal cell carcinoma: in vivo imaging with novel speckle variance optical coherence tomography
 - Nathalie de Carvalho (Moderna, Italy)

About the VivoSight OCT System and Michelson Diagnostics

Michelson Diagnostics develops, manufactures and markets the VivoSight multi-beam Optical Coherence Tomography ('OCT') scanner, a non-invasive, point-of-care, real-time tissue-imaging device. The patented technology, which has CE/TGA regulatory-clearance and FDA 510(k) clearance in the United States, provides clinicians with continuous images of the epidermis and superficial dermis of the skin that can be interpreted by a trained medical professional to aid their assessment of the patient's condition. Given the unprecedented image resolution and image quality, VivoSight OCT has many potential clinical applications beyond the initial focus in dermatology.

The Company's vision is for the VivoSight OCT system to become the standard-of-care for the non-invasive diagnosis and treatment monitoring of certain diseases and conditions that affect cutaneous and epithelial linings of the body. Michelson Diagnostics currently generates revenues from the first commercial application of VivoSight, in the diagnosis of non-melanoma skin cancer (NMSC).

VivoSight has regulatory clearance in Europe, the USA and Australia, for use by trained clinicians in their assessment of the patient's medical condition. VivoSight is currently sold in Germany where the scans are reimbursed for patients with private healthcare insurance. Further clinical studies are presently being conducted at leading centres in the United States.

Michelson Diagnostics, based in Maidstone, Kent, was founded in 2006 and has 20 employees, and has offices in Germany and USA. It is supported by syndicate of venture capital, corporate and private investors, including funds managed by Octopus Investments, Smith and Nephew, Catapult Ventures and Angel Investors.

For more information about Michelson Diagnostics and the VivoSight system, see www.vivosight.com.